Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. The FDA also approved a companion diagnostic to help identify patients ...

Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

HIV product sales were up 6% in 2025, driven by 7% growth in Biktarvy and a 47% surge in its prevention portfolio. This ...

CorMedix (NasdaqGM:CRMD) has approved a $75 million share repurchase program. The company is advancing clinical and pipeline ...

Organon & Co. (NYSE:OGN) Q4 2025 Earnings Call Transcript February 12, 2026 Organon & Co. misses on earnings expectations.

Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire ...

For the year, the portfolio participated strongly, returning 14.28% (investor share), but trailed the index’s 15.91% return.

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.

Belen Garijo ​will succeed Paul Hudson​ as CEO following a string of clinical setbacks at the drugmaker.

With its entrenched retail standing and unrelenting focus on investing in its leading brand mix, Clorox has withstood the onslaught of pressures from covid, supply chain angst, rampant inflation, and ...

The FDA rejected Moderna's experimental flu vaccine Tuesday in a move that proved to be a blow to recently hot Moderna stock.